ProCE Banner Activity

Call to Action: Misperceptions on TROP2-Targeted Antibody–Drug Conjugates in Lung Cancer

Clinical Thought

In this commentary, Stephen Liu, MD, reflects on key misperceptions revealed by a survey of oncology healthcare professionals on emerging TROP2-targeted antibody–drug conjugates for the treatment of patients with lung cancer, including how these agents work, how well they work, and how to identify patient candidates.

Released: February 24, 2023

Expiration: February 23, 2024



Stephen V. Liu

Stephen V. Liu, MD

Associate Professor of Medicine
Director, Thoracic Oncology
Head, Developmental Therapeutics
Georgetown University
Washington, DC

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner



Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Stephen Liu, MD: consultant/advisor: AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech/Roche, Gilead, Guardant Health, Janssen, Jazz, Merck, Merus, Novartis, Regeneron, Sanofi, Takeda, Turning Point Therapeutics; researcher (paid to institution): Alkermes, Elevation Oncology, Genentech, Gilead, Merck, Merus, Nuvalent, RAPT, Turning Point Therapeutics; data and safety monitoring board: Candel Therapeutics.